Article
The ASCENT Trial: a phase 2 study of induction and consolidation afatinib and chemoradiation with or without surgery in stage III EGFR-mutant NSCLC.
The oncologist - 5 Jul 2024
Chang Allison E B, Piper-Vallillo Andrew J, Mak Raymond H, Lanuti Michael, Muzikansky Alona, Rotow Julia, Jänne Pasi A, Mino-Kenudson Mari, Swanson Scott, Wright Cameron D, Kozono David, Marcoux Paul, Piotrowska Zofia, Sequist Lecia V, Willers Henning
Abstract excerpt
BACKGROUND: The role of tyrosine kinase inhibitors (TKIs) in early-stage and metastatic oncogene-driven non-small cell lung cancer (NSCLC) is established, but it remains unknown how best to integrate TKIs with concurrent chemoradiotherapy (cCRT) in locally advanced disease. The phase 2 ASCENT trial assessed the efficacy and safety of afatinib and cCRT with or without surgery in locally advanced epidermal growth...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.